Regenexx, a nationwide network of doctors specializing in regenerative medicine and advanced interventional orthopedic techniques, announced the results of a peer-reviewed research study of 840 patients treated for knee osteoarthritis. All patients were treated using precise imaging guidance and the patented Regenexx protocol, which obtains stem cells from the patient’s own bone marrow.
“We’re proud to say that this study represents the largest published human experience with stem-cell injections to treat knee arthritis to date,” stated Christopher Centeno, M.D., the company’s CEO. “No group has published more data on same-day stem-cell procedures to treat common orthopedic conditions without surgery.”
The research study on knee osteoarthritis examined the efficacy and safety of bone marrow and bone marrow plus fat stem-cell injections. Most of the study patients were knee-replacement candidates. Many patients in the study were able to avoid knee replacement. Self-rated functional and pain scores all showed statistically significant positive changes from baseline in both treatment groups. The study concluded that there was no advantage of adding fat to the joint over just bone-marrow stem cells. Safety in both groups was excellent compared to knee replacement.
It’s important to note that these studies represent data collected in the Regenexx registry as patients are treated and that this data wasn’t collected as part of a randomized controlled trial of the type commonly used in drug studies. The company currently is funding three such trials, one in Chicago and two in Colorado.
To read the full text of the Regenexx study: http://www.regenexx.com/wp-content/uploads/2014/09/370621-1.pdf
“Regenexx Knee Osteoarthritis Stem-Cell Treatment Study Results” first appeared as a post on the Regenexx blog.